Oslo, 05 May 2025 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and
trusted supplier of high-quality prescription, consumer health, and hospital
products to hospitals and pharmacies, today announced it has launched Eroxon®, a
clinically proven over-the-counter topical treatment for the treatment of
erectile dysfunction in men, in Denmark.
The product launch marks the fourth launch of Eroxon® in the Nordics since
Navamedic introduced the product to the Norwegian market in February 2024. As
part of Navamedic's Consumer Health area, Eroxon® will be available to Danish
consumers, without a prescription, across pharmacies.
Ahead of the launch, Navamedic carried out a study through YouGov1[1]. According
to the study, more than 500,000 Danish men over the age of 18 have experienced
erectile problems, and 23 per cent of Danish men have erectile dysfunction (ED).
The study also revealed that four out of ten men who have experienced ED feel it
has impacted either their confidence or quality of life.
"These results are not surprising and confirm how widespread erectile problems
are. It is still taboo to experience erectile problems, and it has a significant
psychological aspect, which we can see with 39 per cent of men where it has
affected their self-confidence or quality of life. We want to change that, and
we need to have the courage to talk about men's sexual health," says Fredrik
Hultberg, Country Manager at Navamedic.
Including the launch of Eroxon® in Denmark, the product is now available to
consumers in Norway, Sweden and Finland. Eroxon® offers a range of features
which differentiates it from other forms of treatments for erectile dysfunction.
It is an effective and fast-acting gel which typically helps men get an erection
within ten minutes of application. It has a good safety profile due to its local
effect with no systemic absorption. Eroxon® has been approved as a treatment for
erectile dysfunction in the EU and the US.
"We are confident that Eroxon® will be a success in Denmark. Until now, Danish
pharmacies have lacked a non-prescription product to treat ED. Based on the
recent study, Danish men are looking for a treatment that can quickly provide an
erection, and we believe Eroxon® meets that desire as it works within 10
minutes," added Fredrik Hultberg, Country Manager at Navamedic.
1] About the study
The survey was conducted by the research institute YouGov. A total of 1,526 CAWI
interviews were conducted with Danish men and women aged 18-89 years from March
26 to April 1, 2025.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com
About Navamedic
Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's
quality of life by being a reliable supplier of high-quality prescription,
consumer health, and hospital products to hospitals and pharmacies. Our growing
product portfolio has been carefully selected to meet current public health
concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to
empower people to live healthier and more fulfilling lives. What sets us apart
is our deep-rooted commitment to understanding the needs and requirements of the
countries where we are present. Our local insight and competence enable us to
understand the specific needs of each country where we operate and ultimately to
gain market access. This makes us a preferred partner for international
companies expanding their footprint across the Nordics and Benelux regions,
through either in-licensing or out-licensing. Navamedic has been listed on the
Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo,
Norway.
For more information, please visit Navamedic.com.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.